Optimizing The Searching For H. Pylori In Clinical Practice With Endofaster (R)

Background/Aim: H. pylori plays a major role in gastroduodenal diseases. Since its incidence is decreasing in developed countries, gastric biopsies were negative in several patients managed in clinical practice. We tested whether EndoFaster (R) - a device allowing real-time H. pylori detection by gastric juice analysis - may optimize the need of biopsies.Methods: In this prospective, multicentre study, the accuracy of EndoFaster (R) for H. pylori detection was computed by using histology of gastric biopsies as a gold standard.Results: Data of 525 consecutive patients were available, including 90 (17.1%) patients with infection. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy of EndoFaster (R) were 87%, 84%, 53%, 97% and 85%, respectively. The overall accuracy of test was not affected neither by ongoing proton pump inhibitor therapy nor by previous eradication therapy. By using EndoFaster (R) in our series, biopsy sampling could have been eventually avoided in a total of 279 patients, accounting for a reduction of 42.3%, accepting the risk of only 8 false negative cases.Conclusions: The very high NPV of EndoFaster (R) might allow to safely halve the need of taking gastric biopsies in unselected patients managed in clinical practice, avoiding an unavailing consume of health resources. (C) 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.